|
EE04748B1
(et)
*
|
1999-06-21 |
2006-12-15 |
Boehringer Ingelheim Pharma Kg |
Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
|
|
GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
US6861422B2
(en)
*
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
|
US20050043233A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE10349113A1
(de)
*
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
US20050096332A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Boehringer Ingelheim International Gmbh |
Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
|
|
DE102004029784A1
(de)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004033670A1
(de)
*
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
|
US7759485B2
(en)
*
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
|
US7728134B2
(en)
*
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
|
US20060035903A1
(en)
*
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
US20060074088A1
(en)
*
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
|
EP1632493A1
(de)
*
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
CZ2004964A3
(cs)
*
|
2004-09-14 |
2006-03-15 |
Pliva-Lachema A. S. |
Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
|
DE102004058337A1
(de)
*
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
|
ES2364495T3
(es)
|
2005-02-03 |
2011-09-05 |
The General Hospital Corporation |
Método para tratar cáncer resistente a gefitinib.
|
|
JP2009514870A
(ja)
|
2005-11-04 |
2009-04-09 |
ワイス |
ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
|
|
CA2833706C
(en)
*
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
|
PL1948180T3
(pl)
*
|
2005-11-11 |
2013-09-30 |
Boehringer Ingelheim Int |
Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
|
|
JP5241513B2
(ja)
*
|
2006-01-26 |
2013-07-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アミノクロトニルアミノ置換キナゾリン誘導体の合成方法
|
|
US7439358B2
(en)
*
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
|
EP2023912A2
(en)
*
|
2006-05-26 |
2009-02-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds in combination therapy
|
|
TW200808325A
(en)
*
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
|
AU2007299080B2
(en)
*
|
2006-09-18 |
2013-04-18 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring EGFR mutations
|
|
ATE543819T1
(de)
|
2006-10-19 |
2012-02-15 |
Signal Pharm Llc |
Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
|
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
MX2009006345A
(es)
|
2006-12-14 |
2009-06-23 |
Vertex Pharma |
Compuestos utiles como inhibidores de proteina cinasa.
|
|
US20110033528A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Poniard Pharmaceuticals, Inc. |
Stabilized picoplatin oral dosage form
|
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
|
EP2178893A4
(en)
*
|
2007-07-16 |
2012-09-19 |
Poniard Pharmaceuticals Inc |
ORAL FORMULATIONS FOR PICOPLATIN
|
|
EP2185559A1
(en)
*
|
2007-08-03 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Crystalline form of a dihydropteridione derivative
|
|
US8754094B2
(en)
*
|
2007-08-15 |
2014-06-17 |
The Research Foundation Of State University Of New York |
Methods for heat shock protein dependent cancer treatment
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
AU2016225895B2
(en)
*
|
2007-10-17 |
2018-02-08 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009099649A1
(en)
*
|
2008-02-08 |
2009-08-13 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin and bevacizumab to treat colorectal cancer
|
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
|
AU2015227503B2
(en)
*
|
2008-06-06 |
2017-02-23 |
Boehringer Ingelheim International Gmbh |
Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
|
|
PE20100252A1
(es)
*
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
PT2293795E
(pt)
*
|
2008-06-06 |
2015-11-17 |
Boehringer Ingelheim Int |
Combinação farmacêutica
|
|
US20170065529A1
(en)
|
2015-09-09 |
2017-03-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical dosage form for immediate release of an indolinone derivative
|
|
MX2010013203A
(es)
*
|
2008-06-06 |
2011-02-25 |
Boehringer Ingelheim Int |
Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona.
|
|
UA107560C2
(uk)
*
|
2008-06-06 |
2015-01-26 |
|
Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
|
|
ES2692769T3
(es)
|
2008-06-17 |
2018-12-05 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
|
MX2011000026A
(es)
*
|
2008-06-23 |
2011-02-24 |
Vertex Pharma |
Inhibidores de proteina cinasas.
|
|
CN105147713A
(zh)
|
2008-08-04 |
2015-12-16 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
|
JP2012509878A
(ja)
*
|
2008-11-21 |
2012-04-26 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
ドセタキセルおよびアンチセンスオリゴヌクレオチドを含む、抗腫瘍併用療法
|
|
WO2010064422A1
(ja)
*
|
2008-12-02 |
2010-06-10 |
静岡県公立大学法人 |
ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
|
|
SG174382A1
(en)
|
2009-04-06 |
2011-11-28 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
|
KR101224468B1
(ko)
*
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
PL2451445T3
(pl)
|
2009-07-06 |
2019-09-30 |
Boehringer Ingelheim International Gmbh |
Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
|
|
ES2543280T3
(es)
*
|
2009-08-10 |
2015-08-17 |
Board Of Regents, The University Of Texas System |
Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
CN102020643A
(zh)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
PH12012500901A1
(en)
|
2009-11-05 |
2016-08-05 |
Rhizen Pharmaceuticals Sa |
Novel benzopyran kinase modulators
|
|
EP2531194B1
(en)
*
|
2010-02-03 |
2018-04-18 |
Signal Pharmaceuticals, LLC |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
EP2536725B1
(en)
*
|
2010-02-17 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones, method for production and use thereof
|
|
CN103180318B
(zh)
|
2010-05-14 |
2017-05-10 |
达那-法伯癌症研究所 |
雄性避孕组合物以及使用方法
|
|
US20110280862A1
(en)
*
|
2010-05-14 |
2011-11-17 |
The University Of Hong Kong |
Gep and drug transporter regulation, cancer therapy and prognosis
|
|
PL2902030T3
(pl)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Związki tienotriazolodiazepinowe do leczenia nowotworu
|
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
AU2011261375B2
(en)
|
2010-06-04 |
2016-09-22 |
Albany Molecular Research, Inc. |
Glycine transporter-1 inhibitors, methods of making them, and uses thereof
|
|
PT2608792T
(pt)
|
2010-08-26 |
2018-01-15 |
Boehringer Ingelheim Int |
Métodos de administração de um inibidor de egfr
|
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
WO2012079075A1
(en)
|
2010-12-10 |
2012-06-14 |
Concert Pharmaceuticals, Inc. |
Deuterated phthalimide derivatives
|
|
CA2827770A1
(en)
|
2011-02-25 |
2012-11-01 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
|
HRP20190128T1
(hr)
|
2011-05-04 |
2019-03-08 |
Rhizen Pharmaceuticals S.A. |
Novi spojevi kao modulatori protein kinaza
|
|
US20130131069A1
(en)
*
|
2011-05-13 |
2013-05-23 |
Boehringer Ingelheim International Gmbh |
Method for treatment of solid malignancies including advanced or metastatic solid malignancies
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
US9370535B2
(en)
*
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
|
WO2013130849A1
(en)
|
2012-02-29 |
2013-09-06 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
US9249093B2
(en)
|
2012-04-20 |
2016-02-02 |
Concert Pharmaceuticals, Inc. |
Deuterated rigosertib
|
|
CN109970742A
(zh)
|
2012-07-04 |
2019-07-05 |
理森制药股份公司 |
选择性PI3Kδ抑制剂
|
|
JP2015524400A
(ja)
|
2012-07-19 |
2015-08-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
|
|
EP3626309B1
(en)
*
|
2012-08-13 |
2023-03-08 |
The Rockefeller University |
Lxrbeta agonist for the treatment of cancer
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
US9643950B2
(en)
|
2012-10-22 |
2017-05-09 |
Concert Pharmaceuticals, Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
|
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
US9782427B2
(en)
|
2013-04-17 |
2017-10-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
|
TW201527300A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
|
|
BR112015026297B1
(pt)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
|
|
US9937169B2
(en)
|
2013-04-17 |
2018-04-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
|
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
|
|
BR112015026292B1
(pt)
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
|
AU2014254052B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
EP3003313A1
(en)
|
2013-05-29 |
2016-04-13 |
Signal Pharmaceuticals, LLC |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
AU2014292888B2
(en)
|
2013-07-25 |
2018-03-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
KR20160037233A
(ko)
*
|
2013-07-26 |
2016-04-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브
|
|
US20150031699A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
|
JP2016525531A
(ja)
*
|
2013-07-26 |
2016-08-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ
|
|
CA2929652A1
(en)
|
2013-11-08 |
2015-05-14 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
AR099052A1
(es)
|
2014-01-09 |
2016-06-29 |
Takeda Pharmaceuticals Co |
Derivados de azaindol
|
|
BR112016017045A2
(pt)
|
2014-01-31 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
Derivados de diazepano e usos dos mesmos
|
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
CA2936865A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
WO2015117055A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
SG11201607108XA
(en)
|
2014-02-28 |
2016-09-29 |
Tensha Therapeutics Inc |
Treatment of conditions associated with hyperinsulinaemia
|
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
CN106715437A
(zh)
|
2014-08-08 |
2017-05-24 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
|
KR20170032474A
(ko)
|
2014-08-08 |
2017-03-22 |
다나-파버 캔서 인스티튜트 인크. |
디히드로프테리디논 유도체 및 그의 용도
|
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
|
BR112017008714A2
(pt)
|
2014-10-27 |
2017-12-19 |
Tensha Therapeutics Inc |
inibidores de bromodomínio
|
|
CN111205268B
(zh)
|
2014-10-30 |
2021-01-26 |
康朴生物医药技术（上海）有限公司 |
异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
|
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
HK1256417A1
(zh)
|
2015-09-11 |
2019-09-20 |
达纳-法伯癌症研究所股份有限公司 |
氰基噻吩并三唑并二氮杂环庚三烯及其用途
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
MX2018006499A
(es)
|
2015-11-25 |
2018-08-01 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos.
|
|
DE102017005089A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
|
|
DE102017005091A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
|
|
CN106831765B
(zh)
*
|
2016-12-28 |
2018-12-14 |
郑州大学 |
2-(2,6-二氰基苯基)咪唑并[1,2-α]吡啶类化合物及其制备方法
|
|
KR102318401B1
(ko)
|
2017-02-28 |
2021-10-29 |
강푸 바이오파마슈티칼즈 리미티드 |
신규한 이소인돌린 유도체, 이의 약학 조성물 및 용도
|
|
KR102569052B1
(ko)
|
2017-05-16 |
2023-08-22 |
어빌리티 파마슈티컬스 에스.엘. |
암의 치료를 위한 약제학적 조합물
|
|
EP3641772B1
(en)
|
2017-06-22 |
2023-08-02 |
Celgene Corporation |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
|
CN109776788B
(zh)
*
|
2017-11-14 |
2021-07-30 |
博瑞生物医药（苏州）股份有限公司 |
叶酸受体靶向多臂偶联物
|
|
CN111629725A
(zh)
|
2018-01-25 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
急性骨髓性白血病的组合治疗
|
|
ES2969982T3
(es)
*
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
EP3833353A4
(en)
*
|
2018-08-10 |
2022-08-24 |
Yale University |
Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
|
|
EP3896062A4
(en)
|
2018-12-06 |
2022-06-15 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF ISOINDOLINE COMPOUND
|
|
IL322315A
(en)
|
2019-05-14 |
2025-09-01 |
Provention Bio Inc |
Methods and preparations for preventing type 1 diabetes
|
|
CN110156700A
(zh)
*
|
2019-06-05 |
2019-08-23 |
鲁南制药集团股份有限公司 |
吉非替尼与水杨酸共晶体
|
|
HUE067466T2
(hu)
|
2019-12-13 |
2024-10-28 |
Inspirna Inc |
Fémsók és alkalmazásuk
|
|
AU2021287998B2
(en)
|
2020-06-11 |
2026-03-12 |
Benaroya Research Institute At Virginia Mason |
Methods and compositions for preventing type 1 diabetes
|
|
US12565529B2
(en)
|
2021-05-24 |
2026-03-03 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
WO2025228947A1
(en)
|
2024-04-30 |
2025-11-06 |
Crossfire Oncology B.V. |
Bifunctional compounds capable of inducing degradation of polo-like kinase1
|